US Patent 11440950 Anti-VEGF protein compositions and methods for producing the same

Is a

Patent

Patent attributes

Patent Applicant

Regeneron Pharmaceuticals

Current Assignee

Regeneron Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11440950

Date of Patent

September 13, 2022

Patent Application Number

17378362

Date Filed

July 16, 2021

Patent Citations

‌

US Patent 10576128 Liquid formulation of a VEGF antagonist

‌

US Patent 10626142 Purification platform for bispecific antibodies

‌

US Patent 10646456 Methods of administering amantadine

‌

US Patent 10772972 Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

‌

US Patent 10738130 Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

‌

US Patent 10144944 Methods of cell culture

‌

US Patent 10392430 Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties

‌

US Patent 10400025 VEGF antagonist formulations suitable for intravitreal administration

...

Patent Citations Received

‌

US Patent 12103960 VEGF traps and mini-traps and methods for treating ocular disorders and cancer

Patent Primary Examiner

‌

Maria G Leavitt

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11440950 Anti-VEGF protein compositions and methods for producing the same

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11440950 Anti-VEGF protein compositions and methods for producing the same